Aa
Aa
A
A
A
Close
808353 tn?1238293321

Any news on the Inform -1 trials

Any one have news on this trial for using a new combo of polymearase and protease inhibitors with out interferon and riba? It's been going on in Australia and New Zeland and is a join effort by Rosche, Intermune, and one other. 14 week trial, pills twice a day. No shots not interferon, no riba.

News is supposed to be releases April 25 At ELDS meeting.(might have the acronym wrong)

Anyone?
4 Responses
Sort by: Helpful Oldest Newest
808353 tn?1238293321
I've been on a few Aussie sites, and have posted but the lid is on.  A few of the Aussies think the lab rats had to sign non disclosure agreements.

A few years back I declined a 191 (R2772 now)trial as it was for tolerability and not efficacy.

Now I've put out feelers for any non-responder/relasper trials using this combo but none are published to date although there have been rumors. I did that with VX 850 but started double dosing interferon instead. That may have been a mistake since a friend got on the VX-950 (teleprivar) trial who was a non responder and she's now SVR.

I am not.

Bradlybone

Helpful - 0
732047 tn?1236010444
I also found out last week that one of the companies involved (Pharmasset) uses the high end servers that I design at my day job to model the virus and the molocules used in the inhibitors. So there is a good chance I will get to do a customer visit at their site sometime in the next year or so.

This makes me feel that in some small way I can actually help the cause. Maybe that,s crazy but it makes me feel motivated to design the best servers I possible can. Not just for the company but for all of us.
Helpful - 0
732047 tn?1236010444
Here is the text from the link I posted Friday. Some folk on another forum I visit are checking with some of the Austrailian HCV forums to see if they can get ahold of anyone who was actually in the trials. I've also read that this was tried in chimps with some good results.

FIRST-IN-MAN DEMONSTRATION OF POTENT ANTIVIRAL ACTIVITY WITH A NUCLEOSIDE POLYMERASE (R7128) AND PROTEASE (R7227/ITMN-191) INHIBITOR COMBINATION IN HCV: SAFETY, PHARMACOKINETICS, AND VIROLOGIC RESULTS FROM INFORM-1

Introduction: The combination of two potent direct-acting antivirals (DAAs), targeting two distinct viral enzymes, may offer advantages over single DAA strategies by enhancing potency, reducing the emergence of drug resistance, and possibly eliminating the need for PEG-IFN +/- ribavirin. The combination of R7128/R7227 offers the potential for a highly potent regimen with a high genetic barrier to resistance.


Methods: INFORM-1 is a randomized, double-blind, ascending dose Phase I trial. Treatment-naïve HCV-infected adults (genotype-1), received up to 14d oral combination therapy. Groups A and B received low dose monotherapy with R7128 (A, n=8) 500mg q12h or low dose R7227 (B, n=9) 100 mg q8h on d1-3, both followed by combination R7128/R7227 on d4-7. Groups C-F (8 active/2 placebo) receive 14d R7128 (mg q12h)/R7227 (mg q8h): 500/100, 1000/100, 500/200, and 1000/200. Safety, viral kinetics, resistance, and pharmacokinetics of R7128/R7227 are evaluated in all cohorts.

Results: Groups A-C (n=27) have been completed with no treatment-related SAEs, dose modifications, or discontinuations. Pharmacokinetic analysis confirmed no drug-drug interaction. The HCVRNA change from baseline for both Groups A and B at d7 was similar (combined mean (SD) -3.0 (0.8) Log10 IU/mL). In Group C after 14d low-dose combination, the mean (SD [range]) change from baseline was -3.9 (0.8 [-5.0 to -2.9]) Log10 IU/mL, with 1 patient undetectable (Figure 1). The combination of R7128 and R7227 provided greater than additive antiviral activity, with no viral rebound (sustained viral load increase > 0.5 Log10).

Conclusions: The orally administered combination of low dose R7128 and R7227 provided significant antiviral potency, suppressed viral rebound, and appears safe and well-tolerated for 14 days. Higher doses and twice-daily regimens are being evaluated in additional cohorts. These results confirm for the first time that a protease and nucleoside polymerase inhibitor can be combined in vivo, and remain a promising combination for future treatment.
Helpful - 0
9648 tn?1290091207
Fancy meeting you here. :)

This was posted earlier today. I think it's what you're talking about:

http://www.medhelp.org/posts/show/797886
Helpful - 0
Have an Answer?

You are reading content posted in the Hepatitis C Community

Top Hepatitis Answerers
317787 tn?1473358451
DC
683231 tn?1467323017
Auburn, WA
Learn About Top Answerers
Didn't find the answer you were looking for?
Ask a question
Answer a few simple questions about your Hep C treatment journey.

Those who qualify may receive up to $100 for their time.
Explore More In Our Hep C Learning Center
image description
Learn about this treatable virus.
image description
Getting tested for this viral infection.
image description
3 key steps to getting on treatment.
image description
4 steps to getting on therapy.
image description
What you need to know about Hep C drugs.
image description
How the drugs might affect you.
image description
These tips may up your chances of a cure.
Popular Resources
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.